Replies to post #63653 on Biotech Values

[microcapfun]

Incyte

>>I wish them the best in their CCR5 efforts—as long as they don’t get into the NNRTI arena<<

Incyte got some pretty good P2 results and then stopped development and said they would outlicense that one and concentrate on the rest of their pipeline - especially their JAK inhibitor program.

Seems to be too many CCR5 antagonists out there. Not sure they will be successful finding a buyer. It's been a few months already ...

micro

[microcapfun]

>>p.s. You ought to be able to nail the Quadro quiz.
<<

I don't usually pay attention to the quizzes, which I find a distraction. No offense. But I guess Elvitegravir is probably in there.

micro